Cannabinoid compositions, and uses thereof in treatment of neurodegenerative diseases or disorders and cancers
AssigneeBiopharmaceutical Research Company
InventorsMichael Hunter LAND, George Bennett HODGIN, Brian Kent BRANDLEY, Lucas J. ZUMSTEIN
Life of this patent
Estimating the term…
Abstract
Cannabinoid compositions formulated for use in the treatment of neurodegenerative diseases and conditions, and cancer are disclosed. The treatment methods herein may be targeting the microtubule associated protein Tau. The compositions include cannabidiol (CBD), cannabigerol (CBG), and tetrahydrocannabinol (THC) as the major components therein, which may be isolated, purified or extracted from cultivars and blended together. The compositions include CBD, CBG and THC in certain ratios, formulated for the use in the treatment of neurodegenerative diseases and conditions, and cancer.
Claims45
A cannabinoid composition, comprising:
- cannabidiol (CBD), cannabigerol (CBG), and tetrahydrocannabinol (THC), collectively a major component of the cannabinoids present in the composition,
- wherein the CBD, CBG and THC are provided as a combination of extracts or isolated from at least two cannabis cultivars.
The composition of any one of the preceding claims, wherein the THC is present primarily in the form of (−)-delta-9-trans-tetrahydrocannabinol (Δ9-THC).
The composition of any one of the preceding claims, wherein the CBD, CBG and THC are collectively greater than 50% by weight of the cannabinoids present in the composition.
The composition of any one of the preceding claims, wherein the CBD, CBG and THC are present in a molar ratio between about 100:100:1 and about 1:1:1.
The composition of any one of the preceding claims, wherein the CBD and CBG are present in a molar ratio between about 100:1 and about 1:1.
The composition of any one of the preceding claims, wherein the molar ratio of CBD and THC is between about 50:1 and about 1:1.
The composition of any one of the preceding claims, further comprising at least one lipid excipient.
The composition of any one of the preceding claims, further comprising docosahexaenoic acid (DHA), or eicosapentaenoic acid (EPA), or a combination thereof.
The composition of any one of the preceding claims, wherein the composition is formulated for oral delivery.
The method of 42 or 43, wherein the treatment at least partially reduces toxic gains of function, and/or at least partially restores or at least partially reduces normal Tau function in the subject.
Dependencies are inferred from the claim text.